Table 2 Clinical assessments and outcomes at inclusion and during follow-up
Measure | Inclusion (n = 165) | 18 months (n = 156) | 30 months (n = 149) |
|---|---|---|---|
Mean M-HAQ score (median) | 0.93 ± 0.64 (0.875) | 0.42 ± 0.50 (0.25) | 0.35 ± 0.41 (0.25) |
No. with M-HAQ ≥ 1.0 (%) | 76 (46.1) | 18 (11.6%) | 17 (11.5%) |
Mean DAS28-3 score (median) | 5.01 ± 1.27 (4.94) | 2.94 ± 1.26 (2.66) | 2.81 ± 1.06 (2.46) |
No. with DAS28-3 < 2.6 (%) | 5 (3.0) | 76 (48.7) | 82 (55.0) |
Mean swollen joint count (median) | 12.55 ± 9.57 (10) | 2.83 ± 5.51 (0) | 2.04 ± 3.64 (0) |
Number without synovitis (%) | n.a. | 72 (46.2) | 82 (55.0) |
Number with persistent arthritis (%) | n.a. | 137 (87.8) | 125 (83.9) |
No. fulfilling criteria for RA (%) | 133 (80.6) | 36 (23.1) | 28 (18.8) |
No. with severe arthritis (%) | 106 (64.2) | 65 (41.7) | 56 (37.8) |
Mean total SvH score (median) | 6.05 ± 8.38 (4) | 11.34 ± 13.82 (7) | 15.76 ± 18.38 (10) |
Mean erosion SvH score (median) | 3.02 ± 4.99 (1) | 6.94 ± 9.37 (4) | 10.31 ± 13.14 (7) |
Upper third of the total SvH score | >5 | >10 | >15 |
No. on DMARDs (%) | |||
Total | 31 (18.8) | 120 (76.9) | 116 (77.9) |
RF-positive | 13/68 (19.1) | 60/63 (95.2) | 60/61 (98.4) |
Anti-CCP-positive | 10/53 (18.9) | 49/52 (94.2) | 50/51 (98.0) |
Anti-Sa-positive | 6/46 (13.0) | 43/45 (95.6) | 44/44 (100.0) |